Results 81 to 90 of about 912,795 (359)
Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro
The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel +15 more
wiley +1 more source
BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy ...
PEGINTERFERON ALFA A. HBEAG NEGATIVE CHRONIC HEPATITIS B. STUDY GROUP +3 more
core
Aim: Cellular CD81 is a well characterized hepatitis C virus (HCV) entry factor, while the relevance of soluble exosomal CD81 in HCV pathogenesis is poorly defined.
Kronenberger Bernd +26 more
core +1 more source
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development [PDF]
Background: Vitamin D insufficiency has been associated with the occurrence of various types of cancer, but causal relationships remain elusive. We therefore aimed to determine the relationship between genetic determinants of vitamin D serum levels and ...
Jörg Bojunga +127 more
core +1 more source
FGL2‐HDAC11 Drives Immunothrombosis via NETs‐Mediated Endothelial Capillarization in MASLD Fibrosis
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is frequently accompanied by hepatic fibrosis and systemic cardiovascular complications; however, the mechanistic interplay between coagulation abnormalities and disease progression remains poorly defined.
Xitang Li +16 more
wiley +1 more source
METABOLIC AND CARDIOVASCULAR COMORBIDITIES IN BULGARIAN PATIENTS WITH CHRONIC VIRAL B AND C HEPATITIS [PDF]
Recent epidemiologic data on chronic viral B and C hepatitis in Bulgaria are limited.The evolution of these infections depends on liver complications and the presence of nonliver comorbidities.
Radoslava Tsrancheva +10 more
doaj +1 more source
Background People with a condition subject to stigmatisation, such as chronic hepatitis B, face the dilemma of whether or not to disclose their status. In Ghana, 12.3% of the adult population has the hepatitis B virus (HBV). One key strategy for breaking
Charles Ampong Adjei +3 more
doaj +1 more source
Hepatitis B Genotypes in Chronic Hepatitis B and Lamivudine Therapy
The influence of hepatitis B virus (HBV) genotypes on the natural history and the response to treatment of patients with chronic hepatitis B are of potential interest. Compared to the patients with HBV genotype C, those with genotype B were of a younger age and had a higher cumulative rate of hepatitis B e antigen (HBeAg) seroconversion during the ...
Tanaka, Y, Lai, CL, Yuen, MF
openaire +4 more sources
Immunotherapy for Chronic Hepatitis B Virus Infection
While new therapies for chronic hepatitis C virus infection have delivered remarkable cure rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal.
A. Bertoletti, N. Le Bert
semanticscholar +1 more source
Engineering Microbial Particles for Next‐Generation Biomedical Platforms
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li +7 more
wiley +1 more source

